Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas
| Autor: | M.J. Morales Lara, C. Funes Vera, M Martínez Penella, V. Jorge Vidal, MC Mira Sirvent, D Lacruz Guzmán |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry Bortezomib Gastrointestinal toxicity Disease progression Event free survival medicine.disease Gastroenterology immune system diseases hemic and lymphatic diseases Internal medicine District hospital Gammopathy medicine business Multiple myeloma Complete response medicine.drug |
| Zdroj: | Farmacia Hospitalaria. 32:280-285 |
| ISSN: | 1130-6343 |
| DOI: | 10.1016/s1130-6343(08)75947-6 |
| Popis: | Objective: To describe the use of bortezomib in a district hospital as an alternative in the treatment of malignant gammopathy. Methods: A retrospective analysis was carried out on patients treated with bortezomib in our hospital between November 2005 and October 2007. The patients’ medical histories were used to obtain data regarding diagnosis, treatments prior to bortezomib, date of the last disease progression, number of bortezomib courses, response to bortezomib, overall and event free survival. Results: 47% of the patients studied were male (5/12). The median age was 67, (age range between 40 and 81). The main diagnosis was multiple myeloma on its own or associated with plasmocytoma. Bortezomib initiation coincided with the last disease progression in 83% of patients (10/12). 50% of the patients completed 7-8 courses of bortezomib. Response was seen in 58% of the patients (7/12), partial response in 33% of them (4/12) and complete response in 25% (3/12). The most common adverse reactions were neuropathy and gastrointestinal toxicity which required treatment to be discontinued in 50% of cases. Conclusions: According to the results obtained, bortezomib is a good alternative in the treatment of malignant gammopathy, above all in the case of plasmocytomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|